MaxCyte is a leading commercial cell-engineering company focused on providing platform technologies to advance innovative cell-based research as well as next generation cell therapeutic discovery, development and commercialisation.

Over the past 20 years, MaxCyte has developed and commercialised their proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Their ExPERT™ platform, which is based on their Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilised across the continuum of the high-growth cell therapy sector, from discovery and development through to commercialisation of next generation, cell-based medicines.

The ExPERT™ family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of Processing Assemblies (consumables); and software protocols, all supported by a robust worldwide intellectual property portfolio. ExPERT™ cGMP Processing Assemblies provide the scales and quality assurance required for clinical research and production in GMP clean-room facilities. All Processing Assemblies are produced using high quality medical grade materials that are thoroughly tested for function, sterility, endotoxin, and particulates. These products are included in the Masterfile at the US FDA and similar regulatory agencies globally to support IND applications.